Roberts recently penned a lengthy tribute to William Howard Taft, one that observers say reflects as much on Roberts’ own judicial record as on Taft’s historical contributions. Taft remains a unique figure
Forecasters are warning that a powerful El Niño weather pattern is building, with significant consequences for California industrial facilities managing stormwater obligations. According to NOAA’s Climate Prediction Center, El Niño carries a
More
Elizabeth Oyer served as the pardoning attorney for the Department of Justice for 13 years before finding herself at the centre of a politically charged Senate confirmation hearing. Last week, Oyer testified
More
Ralph Lauren (NYSE: RL) has demonstrated notable resilience in the consumer discretionary space as the latest quarterly earnings season draws comparisons across apparel and accessories stocks. The apparel and accessories segment remains
More
Investors are increasingly turning to artificial intelligence tools to assess portfolio risk, using platforms like ChatGPT to screen stocks for vulnerability during market downturns. The FTSE 250 index, which tracks mid-cap companies
More
Sarepta Therapeutics has appointed Michael Severino as its next chief executive officer, effective July 28, the rare disease drugmaker announced on Monday. Severino will succeed Doug Ingram, who announced plans to retire
More
The U.S. Supreme Court has agreed to hear RiseandShine Corp. v. PepsiCo, Inc. (PEP), a significant trademark case with wide implications for how infringement disputes are litigated across the country. The dispute
More
Milbank is offering special bonuses of up to $25,000 for associates and counsel, raising fresh questions about whether rival firms will follow suit. The move puts pressure on competitors across the market,
More
D-Wave Quantum (QBTS) has seen its shares climb sharply following two significant developments that have caught the attention of investors and market watchers alike. The company announced a commercial deal with telecommunications
More
Trainline emerged as the top riser on the FTSE 250 index, outpacing peers across the mid-cap benchmark during the latest trading session. The ticketing platform’s gains stood out against a broader market
More
Outlook Therapeutics has secured FDA approval for Lytenava, a reformulated ophthalmic version of Roche’s widely used cancer and eye treatment bevacizumab, after three prior rejections. The New Jersey-based company received the greenlight
More